In Situ Hybridization Market: Introduction
- In situ hybridization is a technique used to label complementary DNA, RNA, or modified nucleic acids strand. The technique helps localize specific DNA or RNA sequence in the small cross-section of tissues or an entire tissue. Hybridization technique is frequently employed for the location of specific nucleic acid sequences on chromosomes or in tissues to understand the organization, regulation, and function of gene.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=56169
- The In situ hybridization technique expands the capabilities to satisfy any therapy needs and enable a new diagnostic, treatment application for patients suffering from cancer or other chronic diseases. Its unique technology in rapid detection of aneuploidies during prenatal stage ensure better functional ability to detect abnormalities related to birth defects or mental disorders. However, inability of probes to detect targeted sequences after few repeats can lead to use of insufficient probes in few regions. This is likely to restrain the adoption of in situ hybridization technique in laboratories.
Request COVID Analysis on In Situ Hybridization Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=56169
Key Drivers, Restraints, and Opportunities of Global In Situ Hybridization Market
- Cases of cancer have been rising globally for the last few years. Extensive studies have been conducted related to human diseases for the last few decades, which have recognized recurrent genomic abnormalities as potential propelling factors for a variety of cancers. Cytogenetic assays, including ISH, help assists in integration of IHC and DNA FISH to complete the in situ toolset for researchers to develop, discover, and implement new-generation diagnostic procedures. Direct imaging of gene expression in situ at the RNA level provides a unique insight into the interplay between cancer cells and the tumour microenvironment while the cancer is in progression. As per GLOBOCAN, in 2018, 43.8 million people were suffering from cancer and 9.6 million deaths occurred due to the cancer. Additionally, approximately 18.1 million new cases were recorded in 2018. The incidence of cancer could increase up to 29.5 million, with a mortality rate of 16.5 million by 2040.
- Furthermore as per the research conducted by McMaster University (Canada), the incidences of haemophilia has tripled to reach 1,125,000, as compared to previous estimates of 400,000. The most affected countries are France, Canada, Italy, Australia, the UK, and New Zealand. This increase is likely to boost the market.
- In developed countries, high-quality molecular diagnostic tests are already available. However, in developing countries, the cost of these diagnostic technologies are higher, which often makes them unaffordable for a large part of the population. However, the lack of a commercial market for diagnostic procedures has resulted in the availability of a small number of diagnostic tests in emerging economies. Consequently, developing countries including India, Brazil, and China, offer significant opportunities for MDx-based technology (including ISH) due to a rise in the geriatric population, increase in incidences of infectious diseases and various types of cancers, expansion of healthcare infrastructure, and surge in investments by respective government bodies and leading players in these countries.
Request Customization on In Situ Hybridization Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=56169
- However, high cost of probes, low detection ability of FISH (fluorescence in situ hybridization) for major abnormalities of patients, and significant time taken by the detection procedures are expected to hamper the in situ hybridization market
North America to Capture Major Share of Global In Situ Hybridization Market
In terms of region, the global in situ hybridization market covers Europe, Latin America, North America, Asia Pacific, the Middle East and Africa. North America dominates the global in situ hybridization market due to an increase in funding for the development of research and healthcare infrastructure and a rise in biomedical research activities in the region. Surge in incidence of chronic diseases and cancer and an increase in the demand for companion diagnostics drive the market in the U.S. This, in turn, is expected to boost the in situ hybridization market in North America.
Europe is the second-largest market for in situ hybridization due to favourable government policies regarding the development of healthcare infrastructure and molecular diagnostic companies engaged in hybridization technique in the region. The market in Asia Pacific is projected to expand at a high growth rate during the forecast period due to an increase in cancer prevalence and diagnosis, changing lifestyle, rise in awareness among patients, and surge in per capita expenditure. Additionally, economic growth in India, China, and the Philippines supports the health care infrastructure as well as expansion of biotechnology companies and pharma labs in these countries. This is expected to fuel the market in Asia Pacific.
Pre Book In Situ Hybridization Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=56169<ype=S
Key Players Operating in Global In Situ Hybridization Market
The global in situ hybridization market is highly fragmented, with the presence of various key players. A large number of manufacturers hold a major share in their respective regions. Major players operating in the global in situ hybridization market are:
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- Merck KgaA
- Advanced Cell Diagnostics, Inc.
- Hoffmann-La Roche
- Agilent Technologies
- Biogenex Laboratories, Inc.
- Exiqon A/S.
- Bio-Techne Corporation
- Qiagen N.V.
- Danaher Corporation
- Perkinelmer
- Enzo Biochem
- Bio-Rad Laboratories
- Abnova Corporation
- Biocare Medical
- Opgen
- Bio Sb
- Genemed Biotechnologies
- Abcam
- Creative Bioarray
- Biocat GmbH
- Zytovision
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”
Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
